Share on StockTwits

Ampio Pharmaceuticals (NASDAQ:AMPE)‘s stock had its “buy” rating reaffirmed by research analysts at Aegis in a report released on Thursday.

Ampio Pharmaceuticals (NASDAQ:AMPE) traded down 24.45% on Thursday, hitting $5.636. The stock had a trading volume of 5,240,100 shares. Ampio Pharmaceuticals has a 1-year low of $5.07 and a 1-year high of $10.86. The stock has a 50-day moving average of $6.83 and a 200-day moving average of $7.0. The company’s market cap is $292.9 million. Ampio Pharmaceuticals also was the target of unusually large options trading on Monday. Stock investors purchased 2,968 put options on the stock. This is an increase of approximately 987% compared to the average daily volume of 273 put options.

Ampio Pharmaceuticals (NASDAQ:AMPE) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.17) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.24) by $0.07. Analysts expect that Ampio Pharmaceuticals will post $-1.05 EPS for the current fiscal year.

Separately, analysts at Jefferies Group initiated coverage on shares of Ampio Pharmaceuticals in a research note on Friday, June 27th. They set a “buy” rating and a $14.00 price target on the stock.

Ampio Pharmaceuticals, Inc (NASDAQ:AMPE) is a development-stage biopharmaceutical company focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.